HC Wainwright & Co. Maintains Buy on Immunic, Lowers Price Target to $5
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $5.
HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $5.